(Q38609875)

4 September 2017

title

Vaccine approaches to malaria control and elimination: Insights from mathematical models (English)

1 reference

4 September 2017

0 references

1 reference

1 reference

Thomas S Churcher

3

0 references

Michael T. White

object named as

Michael T White

series ordinal

1

0 references

Azra Ghani

series ordinal

4

object named as

Azra C Ghani

1 reference

4 September 2017

2

Robert Verity

1 reference

4 September 2017

language of work or name

English

0 references

publication date

14 October 2015

1 reference

4 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

4 September 2017

volume

33

1 reference

4 September 2017

issue

52

1 reference

4 September 2017

page(s)

7544-7550

1 reference

A review of malaria vaccine clinical projects based on the WHO rainbow table

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

A mathematical model of the impact of present and future malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

The role of simple mathematical models in malaria elimination strategy design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

A systematic review of mathematical models of mosquito-borne pathogen transmission: 1970-2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Experimental human challenge infections can accelerate clinical malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Dynamics of the antibody response to Plasmodium falciparum infection in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Duration of humoral immunity to common viral and vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

The design and interpretation of laboratory assays measuring mosquito transmission of Plasmodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

A quantitative analysis of transmission efficiency versus intensity for malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Human-to-mosquito transmission efficiency increases as malaria is controlled

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

Synergism from combinations of infection-blocking malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

7 January 2021

Vaccines against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.099

10.1016/J.VACCINE.2015.09.099

7 January 2021

Identifiers

DOI

1 reference

4 September 2017

1 reference